300858 Beijing Scitop Bio-tech
- 15.62
- +0.19+1.23%
Beijing Scitop Bio-tech News
Cotuo Biotech: Report for the third quarter of 2024
Express News | Beijing Scitop Bio-Tech: Shareholders collectively plan to reduce their shareholding by no more than 4% of the company's shares
beijing scitop bio-tech (300858.SZ): The food sector's research and development production base project is expected to reach the scheduled usable state on June 30, 2025.
Gelonghui, September 20th | Beijing Scitop Bio-Tech (300858.SZ) stated on the investor interaction platform that the food sector research and production base project is expected to reach the planned usable status by June 30, 2025, currently undergoing civil construction work and has signed relevant contracts with major equipment suppliers.
Beijing Scitop Bio-tech (300858.SZ): Postbiotic products can be applied in snack food, daily chemical products, beauty and female personal care products.
Ketuo Biology (300858.SZ) stated on the investor interaction platform that postbiotics refers to genetically defined inactivated microorganisms and/or bacterial components that are beneficial to the host's health, including or excluding their metabolic products; excluding chemically synthesized components and viruses/bacteriophage and their products. Currently, the company's postbiotic products can be applied in snack food, daily chemicals, cosmetics, and female personal care products.
Beijing Scitop Bio-Tech (300858): Probiotics growing rapidly, releasing new production capacity for animal and plant microecological agents.
Event: The company has released its 2024 interim report. In the first half of the year, the company achieved revenue of 0.138 billion yuan, a year-on-year decrease of 1.3%; achieved net income attributable to shareholders of 0.044 billion yuan, a year-on-year increase of 7.9%; achieved non-recurring net income attributable to shareholders of 0.
Beijing Scitop Bio-Tech (300858): The effect of strategic transformation is evident, with high non-GAAP profit growth.
In the overview of the event, Company 24H1 achieved revenue of 0.138 billion yuan, -1.34% year-on-year, achieving a net income attributable to the parent company of 43.51 million yuan, +7.89% year-on-year, achieving a non-net income attributable to the parent company of 37.64 million yuan, +17.3% year-on-year.
Beijing Scitop Bio-tech: Summary of Half-Year Report in 2024.
Beijing Scitop Bio-tech: Half-year report for the year 2024.
Express News | Beijing Scitop Bio-tech: Net income in the first half of the year increased by 7.89% year-on-year.
Scitop Bio-tech's Unit Receives 20 Million Yuan Grant From Government
Express News | Beijing Scitop Bio-tech: Wholly-owned subsidiary received 20 million yuan government subsidy.
Beijing Scitop Bio-Tech (300858.SZ): Inner Mongolia Scitop received a government subsidy of 20 million yuan.
Beijing Scitop Bio-tech (300858.SZ) announced on August 13th that its wholly-owned subsidiary Inner Mongolia Scitop Bio-Tech Co., Ltd. (referred to as Inner Mongolia Scitop) recently received government subsidies of RMB 20 million, accounting for 21.39% of the net income attributable to shareholders of the listed company in 2023 as audited.
Scitop Bio-tech Ties Up With Runhe Supply Chain to Develop Pet Food Probiotics
Express News | Beijing Scitop Bio-Tech: Signed a strategic cooperation agreement with Runhe Supply Chain Group.
Express News | Beijing Scitop Bio-tech: Recently obtained a total of 8 patent certificates.
Express News | Beijing Scitop Bio-tech: Involved in the project and won the second prize of the National Science and Technology Progress Award.
Beijing Scitop Bio-Tech (300858.SZ): Dividends of 1.5 yuan per share will be distributed 10 times for the year 2023, with a record date of July 2nd.
On June 25th, Gelunhui reported that Beijing Scitop Bio-Tech (300858.SZ) announced its 2023 annual equity distribution plan: Based on the company's existing total share capital of 263,495,118 shares, RMB 1.500000 cash (including tax) will be distributed to all shareholders for every 10 shares held. The equity distribution equity registration date for this time is July 2nd, 2024, and the ex-rights and ex-dividend date is July 3rd, 2024.
Beijing Scitop Bio-tech (300858): Three major sub-brands debut at new product launch conference, and the core business of probiotics is promising.
Event: Recently, the company held a press conference for China's mushrooms titled 'The Road to Find Mushrooms in 21 Years: Unlocking the Health of the Chinese People.' The conference showcased a newly designed innovative probiotics terminal product and featured three sub-brands: Probiotic brand Yishiyou, MBB, and Housheng.
Ketuo Biotech (300858) Company In-depth Research Report: Equity Incentives+Production Capacity Landed, Probiotics Leading the Way and Set Sail
The compounding business has a deep foundation. The second curve of probiotics opens up space. The company started with compounding food additives and has been deeply involved in the field of segmentation for more than ten years, forming a deep technical accumulation and customer base, and reaching stable cooperative relationships with many leading dairy companies. Based on this, the public
Cotuo Biotech (300858.SZ) grants 2.6 million restricted shares at a grant price of 13 yuan/share
Ketuo Biotech (300858.SZ) announced that restricted shares stipulated in the company's 2024 restricted stock incentive plan...
Analysis
Price Target
No Data
No Data